This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Commentary

Defining and Managing Suicidal Risk in Patients Taking Psychotropic Medications

Jan A. Fawcett, Ross J. Baldessarini, William H. Coryell, Morton M. Silverman, and Dan J. Stein

Published: June 15, 2009

Article Abstract

In March 2004, the US Food and Drug Administration (FDA) issued
a public health advisory warning that antidepressant treatment may
increase suicidality and worsen depression in adult and pediatric patients.
Then, in May 2007, the FDA proposed that the black box warning in the
prescribing information for antidepressants and other drugs used to treat depression
be updated to include a warning about an increased risk of suicidality
in young adults. In January 2008, the FDA announced that antiepileptic
medication labeling will be required to include a warning about an
increased risk of suicidality.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 70

Quick Links: Depression (MDD) , Suicide

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or...

Read More...